Skip to main content
Download PDF

In emergency hypertension, could biomarkers change the guidelines?

BMC Cardiovascular Disorders volume 24, Article number: 152 (2024) Cite this article

Abstract

Background

Hypertension may cause target organ damage (TOD). Target blood pressure (BP) management may not be appropriate in some conditions.

Aim

We aim to assess the impact of targeted BP management in severe hypertension on renal TOD.

Patients & methods

This is a prospective cohort study involving patients admitted due to severe hypertension (BP > 180/120) associated with any symptoms. The study involved patients referred to the ICU in our tertiary center during the period between August 2017 and February 2018. All patients underwent target BP treatment according to recent guidelines. Hs-Troponin T (hs-TNT) and serum creatinine (s.creat) were measured in all patients on admission and 24 h later. Patients were divided into Group A (with initial normal hs-TNT) and Group B (with initial high hs-TNT). The main outcome was in-hospital renal-related morbidity (including renal failure).

Results

Four hundred seventy consecutive patients with hypertensive crises were involved in the study. Group B had a significantly higher incidence of in-hospital mortality (4 patients) and renal TOD (acute renal dysfunction) than Group A (P value = 0.001 and 0.000 respectively). There was a significant difference between initial s.creat on admission and follow-up s.creat values in Group B with significant elevation of their s.creat on the following 24 h (P = 0.002), while this difference is insignificant in Group A (P = 0.34). There was a significant positive correlation between hs-TNT and the follow-up s.creat (P = 0.004).

Conclusion

In severe HTN, hs-TNT may be elevated due to marked afterload. Patients with severe HTN and high hs-TNT have higher s.creat values, which are associated with an increased risk of renal failure and in-hospital mortality if their BP decreases acutely to the guideline-target BP. Using biomarkers during the management of emergency HTN should be considered before following clinical guidelines. However, our findings do underscore the potential utility of hs-TNT as an indicator for risk stratification in patients with severe or emergency HTN.

Key points

AbstractSection Question

What is the relationship between troponin in emergency hypertension and the in-hospital outcome of the application of guidelines-targeted blood pressure control?

AbstractSection Findings

In this cohort study that included 470 adults, patients with emergency hypertension with positive troponin had worse in-hospital outcomes with increased incidence of renal dysfunction if they were treated to guidelines target blood pressure.

AbstractSection Meaning

In emergency hypertension, the management of patients should be individualized according to the results of biomarkers.

Introduction

Hypertension (HTN) is still considered a major cause of cerebrovascular disease, with approximately 30% of adults currently diagnosed as hypertensive in the USA [1]. In addition, many hypertensive patients have uncontrolled blood pressure (BP) leading to the risk of target organ damage (TOD) [2, 3]. It is necessary to identify hypertensive patients who are at risk of developing target organ damage.

Although the diagnosis of hypertension is made when BP reaches certain thresholds, TOD due to high BP occurs on a continuous spectrum. Indeed, even early, pre-hypertensive, state may induce structural heart changes [4].

Some laboratory and electrocardiographic markers may have a role in predicting the worse prognosis of hypertension [5, 6].

Cardiac troponin I (cTnI) and T (cTnT) are the most sensitive and specific biochemical markers of myocardial cell damage [7]. They have the ability.

to detect even microscopic necrosis of myocardium [8]. These assays can detect subclinical myocardial damage in a significant proportion of patients who have no apparent cardiovascular disease [9, 10]. Thus, hs-cTNT may help identify individuals who are at risk of developing hypertensive cardiac end-organ damage, such as LVH.

Attention regarding (BP) treatment targets has been regained, and the outcome of the aggressive approach in lowering blood pressure to < 120/80 mmHg in high-risk hypertensive patients is a debatable issue [11].

The question is “Is target BP suitable for all patients? Or it should be individualized?”. Another question should be addressed; “ Is there any biomarker that could be used for guiding our goals of therapy?”

Aim of the work

Our study aims to assess the impact of guidelines-targeted BP treatment in severe hypertension on renal TOD during the in-hospital course. In addition, we aim to find out the significance of the simple biomarker hs-TNT in guiding the management of severe HTN.

Patients & methods

All patients admitted to our center due to severe hypertension (BP > 180/120) [10] associated with any symptoms during the period between August 2017 and February 2019 were enrolled in this study.

Patients were excluded from this study if they:

  1. (a)

    had myocardial infarction, either STEMI or Non-STEMI;

  2. (b)

    already had renal failure or on hemodialysis;

  3. (c)

    had a fever or any signs of infection.

  4. (d)

    presented with acute aortic dissection.

  5. (e)

    presented with acute stroke or cerebral hemorrhage.

  6. (f)

    presented with eclampsia or pre-eclampsia.

Thorough clinical examination and rapid echocardiography were done for all patients. All patients were managed according to guidelines [12,13,14]. Nitroglycerin infusion, due to its availability in our center, was used with titrated doses beginning with 5ugm/min increased every 3–5 min according to BP response to a maximum dose of 100ugm/min till reached the guideline target BP followed by gradual weaning. Continuous hemodynamic monitoring with careful titration according to BP response was done.

Guideline targeted BP was achieved in all patients during their hospitalization as follows: SBP has been reduced by no more than 25% within the first hour; then, if stable, to 160/100 mm Hg within the following 2 to 6 h; and then gradually to normal [12, 15].

After initiation of IV treatment, we added ACEI, ARBs, or BB according to the case scenario, as oral therapy with these agents may be very useful in malignant HTN in which the renin system is activated due to renal ischemia [15].

On admission, hs-TnT concentration was measured, using an Elecsys 2010 system (Roche Diagnostics, Basel, Switzerland), and serum creatinine (s.creat) was measured using Chemistry Analyzer AU480 (Beckman Coulter Inc., USA).

This hs-cTnT assay measures values in the range of 3 to 100,000 ng/L.

The follow-up tests were done 24 h later.

Patients were divided into 2 groups according to their initial hs-TNT values; Group A with initial normal hs-TNT values (< 0.003 ng/ml) and Group B with initial high hs-TNT values (> 0.003 ng/ml).

In-hospital morbidity and mortality were recorded for all patients.

IRB approval was obtained, and written informed consent was obtained from each patient.

Statistics

SPSS version 2010 was used for data analysis. Continuous Variables are expressed as mean ± SD while categorical variables are expressed in frequency and percentage. Differences in the frequency of characteristics were assessed by independent sample student’s t-test for continuous variables, while Chi-square statistics were used for discrete variables. A two-tailed P-value, 0.05 was considered statistically significant.

Variables that had not fulfilled the normal distribution frequency conditions were treated by non-parametric tests (Mann-Witney test) or (Wilxocon test).

Logistic regression analysis was done to model the dependent and independent variables and make a univariate analysis; P-value of 0.05 was considered statistically significant.

Results

Four hundred ninety-five consecutive patients with hypertensive crises with different profiles were admitted. Twenty-five patients were excluded. The remaining 470 patients were enrolled in this cohort prospective. Figure 1 shows the different symptoms associated with HTN in the study populations.

Fig. 1
figure 1

Shows the clinical presentations of patients with hypertensive crisis

Full size image

One hundred eighty patients had initial normal Hs-TNT (Group A) and 290 patients had initial high Hs-TNT (Group B).

None of the patients in either group had the history of intake of nephrotoxic drugs over the past 3 months.

Regarding BP

Mean blood pressure measurements were (226 ± 25 for systolic, 118 ± 16 for diastolic, and 149 ± 17 for mean BP) on admission, and (157 ± 21for systolic, 92 ± 13 for diastolic, and 113 ± 16 for mean BP) 24 h after initiation of treatment. The mean duration of treatment till control of BP was 10.5 ± 5.2 h for group A and 18.7 ± 7.2 h for group B (P = 0.000).

Regarding laboratory results

Hs-TnT was ≥ 0.003 ng/ml in 290 patients (Group B), with mean of 0.270 ± 0.019 ng/ml (range 0.003—0.308), while Group A comprised 180 patients with mean hs-TNT value = 0.001 ± 0.0015 ng/ml.

Table 1 presents the difference between both groups on admission.

Table 1 Characteristics of patient populations on admission
Full size table

In group B, the mean s.creat on admission was 1.47 ± 0.12 mg/dl and 2.6 ± 0.8 mg/dl 24 h later (P value = 0.001), while this difference was insignificant in Group A (P = 0.34).

There was a weak positive correlation between hs-TNT and initial (admission) s.creat (P = 0.06) in the whole study population but a highly significant positive correlation between hs-TNT and the follow-up (24-hour post-admission) s.creat (P = 0.004).

Raised initial hs-Troponin has shown to have a greater statistical power in predicting renal dysfunction in severe hypertensive patients undergoing guideline target BP control (Observed power = 0.89).

Regarding the outcome

In group A, there was one death due to extensive cerebral infarction on the following day of admission, while in group B, there were 4 deaths due to massive cerebral hemorrhage in 2 cases and acute heart failure in the other 2 cases (diagnosed clinically and by depressed EF less than 40%) (P value = 0.01).

Group B had a significantly higher incidence of in-hospital renal dysfunction than group A (P value = 0.001) (Table 2).

Table 2 Difference between both groups in morbidity & mortality
Full size table

Twenty-three patients in group B developed acute renal failure after control of BP to the guideline level, while 130 cases developed moderate renal dysfunction in the form of rising s.creat and reduction of eGFR during in-hospital stay.

The multivariate analysis shows that hs-TnT is still the only independent predictor of renal dysfunction in severe hypertensive patients undergoing guideline target BP control, even after controlling for smoking, systolic blood pressure, diastolic blood pressure, and initial s.creatinine. The coefficients for smoking, systolic BP, diastolic BP, and initial s.creatinine indicate their respective contributions to the likelihood of renal dysfunction after controlling for the other variables in the model (Table 3).

Table 3 Multivariate analysis for predictors of renal dysfunction in severe hypertensive patients undergoing guideline target BP control
Full size table

The regression analysis shows that hs-TnT is the only independent predictor of renal dysfunction in severe hypertensive patients undergoing guideline target BP control (Table 4).

Table 4 Regression analysis for independent predictors of renal dysfunction in severe hypertensive patients undergoing guideline target BP control
Full size table

Discussion

In our cohort, we studied the impact of guidelines-targeted BP control in patients with emergency HTN on their renal outcome. We found that patients with positive hs-troponin on admission have worse outcomes regarding renal dysfunction as well as mortality.

Resultant pressure overload due to severe HTN may result in subclinical myocardial wall remodeling and potential ischemic cardiomyocyte injury [16].

Severe hypertension exerts very high-pressure overload that causes relative ischemia and necrosis or minute damage to myocytes, and thus troponin release. This effect similarly occurs in any other cause of increased pressure loads [17, 18]. In addition, activation of the sympatho-adrenal system in hypertensive patients leads to increased catecholamine release and subsequent myocyte injury [19].

Optimal SBP targets from ACCORD [20], INVEST [21], and ONTARGET [14] seem to be between 120 and 140 mmHg. A comprehensive meta-analysis [22] of 17 trials including SPRINT, aiming at assessing optimal BP targets, found that the balanced efficacy and safety could be achieved at 130 mmHg.

More consideration was given to the results from SPRINT, suggesting reduced CV risk with SBP treatment target at 120 mmHg [23].

The concept of “the lower the better” in case of hypertension in diabetic, renal, or CAD patients should be revised. The guidelines-targeted BP reduction in case of severe hypertension could be changed if we found an increased risk of morbidity and mortality by applying this strategy.

In the current study, we found that emergency hypertensive patients with initially raised hs-TNT had higher in-hospital mortality and morbidity (renal dysfunction) than those with normal hs-TNT when we applied the guidelines in controlling their BP. They developed deterioration of their renal function if their BP was controlled to the guideline level. In addition, the degree of deterioration of s.creat was positively correlated with the initial level of hs-TNT. However, those with initial normal hs-TNT levels would get benefit of guideline-targeted BP control.

Hypertension-induced TOD may affect the kidneys in its early stages. The risk of albuminuria progression was assessed in meta-analysis and found to be significantly reduced after intensive BP control [24].

Another study found that greater proteinuria and reduced eGFR in the general population are associated with masked hypertension [25]. This may suggest that the damaging effect of hypertension might affect the kidney earlier than other organs, causing TOD for the kidney even before the diagnosis of HTN or the occurrence of any symptoms.

In our study, there was a significant difference between both groups with and without elevated hs-TNT regarding initial s-creat, with higher values in group B with elevated initial hs-TNT. This may indicate that the kidney has been already affected by HTN in those patients to a subclinical degree. Therefore, the relatively marked reduction of BP (according to the guidelines target) may disturb the renal autoregulation that seems to be developed with time in those patients.

Our conclusion was supported by another study conducted by Seccia et al. They found that a relatively high proportion of hypertensive patients develop mild-to-moderate hypertensive nephrosclerosis. This pathology was found to progress into end-stage renal disease only in a relatively small percentage, especially those with prolonged uncontrolled SBP [26].

In this context, a more personalized, biomarker-guided, approach to BP treatment in this group with severe HTN may be a preferred alternative.

We hypothesize that target BP should not be a solid figure and should be individualized. It depends on the degree of TOD. Elevated hs-TNT, as an indicator of TOD, could be used to guide BP control. When hs-TNT is not elevated, intense BP control to the guideline-targeted BP could be applied. However, if hs-TNT is elevated during the sitting of severe HTN, more caution should be exerted not to reduce BP markedly or over a short time. In this condition, the reduction of BP just to the level making the hs-TNT value return to normal seems to be appropriate in the first days. Longer duration may be better needed before returning the BP to normal.

Patients with positive hs-troponin on admission may benefit from closer monitoring, cautious blood pressure control over a longer period and potentially more frequent assessment of renal function. These individuals may be at higher risk for renal dysfunction and mortality, so tailoring their treatment approach to address these risks could be beneficial. A multidisciplinary approach involving cardiologists, nephrologists, and intensivists may be considered to optimize the management of these high-risk patients.

In a study done on isolated systolic hypertension in older adults [27], the authors concluded that cardiac biomarkers hs-cTnT and NT-proBNP might be used to identify older adults who would benefit from more intensive BP therapy to reduce systolic hypertension. They thought that high biomarker levels might identify older patients who could benefit from intensive BP treatment. This conclusion may conflict with our findings that intense BP control increases the risk of mortality and renal failure in patients with high hs-TNT. This controversy may be due to the difference in studied populations. Those in our study had severe or emergency HTN, which might differ in their myocardial tolerance to pressure overload and in TOD risk at lower cTnT thresholds.

Cardiac troponins may be elevated in asymptomatic end-stage renal patients [28]. The mechanisms causing such biomarker elevation in renal patients are not clear. There is emerging evidence that troponin elevation in asymptomatic renal patients indicates subclinical myocardial necrosis or minute injury [29].

In a trial aiming to determine the independent risk factors of CKD progression, higher hs-TNT was significantly associated with 1.5-fold of the composite outcome of CKD deterioration. This association was similar to or stronger than that of high systolic BP [30].

The association between cardiac biomarkers such as hs-TNT and NT-proBNP and CKD may indicate their value as markers of cardiorenal syndrome [30, 31].

None of our patients took nephrotoxic drugs over the past 3 months prior to admission. While certain medications, such as ACE inhibitors and angiotensin receptor blockers, can decrease GFR by impacting renal hemodynamics. Drugs that affect kidney perfusion and haemodynamics may safeguard nephrons against hyperfiltration, which can lead to CKD progression [32].

The decrease in all-cause mortality with more intensive blood pressure lowering was also demonstrated in the SPRINT trial; however, in the subgroup of chronic kidney disease, there was not any significant reduction in risk for the primary composite endpoint of cardiovascular morbidity and mortality in those treated with more intensive therapy [33]. Post hoc analysis of some studies demonstrated higher mortality associated with more systolic hypotension [34].

Conclusion

In severe HTN, hs-TNT may be elevated due to marked afterload. Patients with severe HTN and high hs-TNT have higher s.creat values, which are associated with an increased risk of renal failure and in-hospital mortality if their BP decreases acutely to the guideline-target BP. Using biomarkers during the management of emergency HTN should be considered before following clinical guidelines. However, our findings do underscore the potential utility of hs-TNT as an indicator for risk stratification in patients with severe or emergency HTN. Further research with larger and more diverse cohorts is needed to fully assess the role of biomarkers in guiding the management of hypertensive emergencies Hs-TNT should be considered as an indicator to guide the strategy of managing of patients with severe or emergency HTN.

Take-Home message

In the context of severe HTN, biomarker target BP control should be applied instead of guideline target BP control. When hs-TNT and s.creat are elevated, BP should not be markedly reduced, otherwise, renal failure may develop. Nevertheless, BP should be controlled just to the level that makes the hs-TNT value return to normal. However, in patients with normal hs-TNT values, BP could be controlled to the guideline target.

Therefore, target BP should be individualized instead of being a universal value.

Limitations

The previous data on renal function before admission was not available. The study involved a single tertiary center.

Data availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

References

  1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Executive Summary: Heart Disease and Stroke Statistics\&\#x2014;2016 update. Circulation. 2016;133(4):447–54.

    Article  PubMed  Google Scholar 

  2. Egan BM, Control of H. 1988–2008. Hypertension. 2010;303(20):2043–50.

    CAS  Google Scholar 

  3. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA - J Am Med Assoc. 2013;310(9):959–68.

    Article  CAS  Google Scholar 

  4. Stabouli S, Kotsis V, Rizos Z, Toumanidis S, Karagianni C, Constantopoulos A, et al. Left ventricular mass in normotensive, prehypertensive and hypertensive children and adolescents. Pediatr Nephrol. 2009;24(8):1545–51.

    Article  PubMed  Google Scholar 

  5. Karakayali M, Omar T, Artac I, Rencuzogullari İ, Karabag Y, Demir O. The relationship between the systemic immune-inflammation index and reverse-dipper circadian pattern in newly diagnosed hypertensive patients. J Clin Hypertens (Greenwich). 2023;25(8):700–7.

    Article  PubMed  Google Scholar 

  6. Karakayali M, Artac I, Omar T, Rencuzogullari İ, Karabag Y, Cinar T, et al. The association between frontal QRS-T angle and reverse dipper status in newly diagnosed hypertensive patients. Blood Press Monit. 2023;28(2):96–102.

    Article  PubMed  Google Scholar 

  7. Jaffe AS, Ravkilde J, Roberts R, Naslund U, Apple FS, Galvani M, et al. It\&\#x2019;s Time for a change to a Troponin Standard. Circulation. 2000;102(11):1216–20.

    Article  CAS  PubMed  Google Scholar 

  8. Antman E, Bassand JP, Klein W, Ohman M, Lopez Sendon JL, Rydén L, et al. Myocardial infarction redefined - A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee f or the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36(3):959–69.

    Article  PubMed  Google Scholar 

  9. de Lemos JA. Increasingly Sensitive Assays for Cardiac Troponins: A Review. JAMA [Internet]. 2013;309(21):2262–9. https://doi.org/10.1001/jama.2013.5809.

  10. Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS, Boerwinkle E, et al. Cardiac troponin T measured by a highly sensitive assay predicts Coronary Heart Disease, Heart failure, and Mortality in the atherosclerosis risk in communities Study. Circulation. 2011;123(13):1367–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Heimark S, Mariampillai JE, Narkiewicz K, Nilsson PM, Kjeldsen SE. Which Target Blood Pressure in Year 2018? Evidence from Recent Clinical Trials. High Blood Press Cardiovasc Prev [Internet]. 2018;25(2):151–8. https://doi.org/10.1007/s40292-018-0258-z.

  12. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Pr. Hypertension. 2018;71(6):e13–115.

    CAS  PubMed  Google Scholar 

  13. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J [Internet]. 2018;39(33):3021–104. https://doi.org/10.1093/eurheartj/ehy339.

  14. Laurent S, Lip H, McManus GY, Narkiewicz R, Ruschitzka K, Schmieder F. RE, 2018 ESC/ESH Guidelines for the management of arterial hypertension. Available from: www.escardio.org/guidelines.

  15. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J [Internet]. 2018;39(33):3021–104. https://doi.org/10.1093/eurheartj/ehy339.

  16. Myburgh CE, Malan L, Wentzel A, Scheepers JDW, Malan NT. Coping and Cardiac Troponin T – a risk for hypertension and sub-clinical ECG left ventricular hypertrophy: the SABPA Study. Hear Lung Circ. 2019;28(6):908–16.

    Article  Google Scholar 

  17. El Tahlawi M, Morsy M, Elawady M, Abdelaziz M, Eldamanhory A. Is there any relationship between biomarkers and echocardiographic markers in patients with pulmonary stenosis underwent balloon valvuloplasty? Echocardiography. 2021;38(6):924–31.

    Article  PubMed  Google Scholar 

  18. Salama A, Ibrahim G, Fikry M, Elsannan MH, Eltahlawi M. Prognostic value of high-sensitive troponin T in patients with severe aortic stenosis undergoing valve replacement surgery. Indian J Thorac Cardiovasc Surg. 2024;40(2):142–50. https://doi.org/10.1007/s12055-023-01594-5

  19. Barber M, Morton JJ, Macfarlane PW, Barlow N, Roditi G, Stott DJ. Elevated Troponin Levels Are Associated with Sympathoadrenal Activation in Acute Ischaemic Stroke. Cerebrovasc Dis [Internet]. 2007;23(4):260–6. Available from: https://www.karger.com/DOI/https://doi.org/10.1159/000098325.

  20. Hartaigh Ó, Szymonifka B, Okin J. PM. Achieving target SBP for lowering the risk of major adverse cardiovascular events in persons with diabetes mellitus. J Hypertens [Internet]. 2018;36(1). Available from: https://journals.lww.com/jhypertension/Fulltext/2018/01000/Achieving_target_SBP_for_lowering_the_risk_of.16.aspx.

  21. Cooper-Dehoff RM, Handberg EM, Mancia G, Zhou Q, Champion A, Legler UF, et al. INVEST revisited: a review of findings from the INternational VErapamil SR-Trandolapril STudy (INVEST) NIH Public Access. Expert Rev Cardiovasc Ther. 2009;7(11):1329–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Bangalore S, Toklu B, Gianos E, Schwartzbard A, Weintraub H, Ogedegbe G et al. Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta-Analysis of Randomized Trials. Am J Med [Internet]. 2017;130(6):707–719.e8. https://doi.org/10.1016/j.amjmed.2017.01.004.

  23. Cushman WC, Ringer RJ, Rodriguez CJ, Evans GW, Bates JT, Cutler JA, Hawfield A, Kitzman DW, Nasrallah IM, Oparil S, Nord J, Papademetriou V, Servilla K, Van Buren P, Whelton PK, Whittle J, Wright Jr JT, for the SPRINT Research Group. Blood pressure intervention and control in SPRINT. Hypertension. 2022;79(9):2071–80.

  24. Wang J, Chen Y, Xu W, Lu N, Cao J, Yu S. Effects of intensive blood pressure lowering on mortality and cardiovascular and renal outcomes in type 2 diabetic patients: A meta-analysis. PLoS One [Internet]. 2019;14(4). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064379610&doi=10.1371%2Fjournal.pone.0215362&partnerID=40&md5=b8e99446446e08ae630397115c4de9e1.

  25. Babu M, Drawz P. Masked Hypertension in CKD: Increased Prevalence and Risk for Cardiovascular and Renal Events. Curr Cardiol Rep [Internet]. 2019;21(7):58. https://doi.org/10.1007/s11886-019-1154-4.

  26. Seccia TM, Caroccia B, Calo LA. Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms. J Hypertens [Internet]. 2017;35(2):205–12. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.084992416961&doi=10.1097%2FHJH.0000000000001170&partnerID=40&md5=a06a98d7e8a06d21152d73eaba4af292.

  27. Madan N, Lee AK, Matsushita K, Hoogeveen RC, Ballantyne CM, Selvin E et al. Relation of Isolated Systolic Hypertension and Pulse Pressure to High-Sensitivity Cardiac Troponin-T and N-Terminal pro-B-Type Natriuretic Peptide in Older Adults (from the Atherosclerosis Risk in Communities Study). Am J Cardiol [Internet]. 2019;124(2):245–52. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065441958&doi=10.1016%2Fj.amjcard.2019.04.030&partnerID=40&md5=bb83bacb2600dd1d01b45ed2884d62d6.

  28. Castini D, Persampieri S, Floreani R, Galassi A, Biondi ML, Carugo S et al. Troponin I Levels in Asymptomatic Hemodialysis Patients. Blood Purif [Internet]. 2017;44(3):236–43. Available from: https://www.karger.com/DOI/https://doi.org/10.1159/000480225.

  29. Ooi D, Isotalo P, Veinot J. Correlation of antemortem serum creatine kinase, creatine kinase-MB, troponin I, and troponin T with cardiac pathology. Clin Chem. 2000;46 3:338–44.

    Article  Google Scholar 

  30. Anderson AH, Xie D, Wang X, Baudier RL, Orlandi P, Appel LJ, et al. Novel risk factors for Progression of Diabetic and nondiabetic CKD: findings from the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis. 2021;77(1):56–73e1.

    Article  CAS  PubMed  Google Scholar 

  31. Spanaus KS, Kronenberg F, Ritz E, Schlapbach R, Fliser D, Hersberger M, et al. B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the mild-to-moderate kidney disease study. Clin Chem. 2007;53(7):1264–72.

    Article  CAS  PubMed  Google Scholar 

  32. Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders HJ. Acute kidney injury. Nat Rev Dis Prim [Internet]. 2021;7(1). https://doi.org/10.1038/s41572-021-00284-z.

  33. Wright JTJ, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med [Internet]. 2015;373(22):2103–16. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84948439672&doi=10.1056%2FNEJMoa1511939&partnerID=40&md5=bee2a1befd0961f3f91f2b3fd620c4d1.

  34. Hawkins-van der Cingel G, Thuraisingham R. Management of hypertension in renal disease. Medicine (Baltimore) [Internet]. 2019;47(8):523–5. https://doi.org/10.1016/j.mpmed.2019.05.006.

Download references

Acknowledgements

Not applicable.

Funding

The authors received no funding for conducting this study.

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

Author information

Authors and Affiliations

  1. Zagazig University Hospitals, Zagazig, Egypt

    Mohammad El Tahlawi, Scopus Mohamed Ismail, Ahmed Eldamanhory, Ayman Khorshed & Salem M. Salem

  2. University of Central Florida College of Medicine, Graduate Medical Education, Florida, USA

    Scopus Mohamed Ismail

  3. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

    Salem M. Salem

Authors
  1. Mohammad El Tahlawi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scopus Mohamed Ismail
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmed Eldamanhory
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ayman Khorshed
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Salem M. Salem
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ME Analysed the data of patients and was a major contributor in writing the manuscript. MF: Collected the clinical and laboratory data. AE helped in drafting the manuscript. AK helped in collecting the data, revising and editing the language. SS Collected the data, organized and grouped the clinical and laboratory findings.

Corresponding author

Correspondence to Mohammad El Tahlawi.

Ethics declarations

Ethics approval and consent to participate

The study is approved by IRB Zagazig University.

Written informed consent from patients or relatives and approval of the Ethical Committee were taken.

All methods were carried out in accordance with relevant guidelines and regulations.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tahlawi, M.E., Ismail, S.M., Eldamanhory, A. et al. In emergency hypertension, could biomarkers change the guidelines?. BMC Cardiovasc Disord 24, 152 (2024). https://doi.org/10.1186/s12872-024-03785-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12872-024-03785-3

Keywords

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us